Management of erectile dysfunction: Defining the role of sildenafil

Disease Management and Health Outcomes

Volumn 10, Issue 7, 2002, Pages 431-452

  Lyseng Williamson, Katherine A ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Disease management; Erectile dysfunction; Review on treatment; Sildenafil

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; APOMORPHINE; ORGANIC NITRATE; PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

COST EFFECTIVENESS ANALYSIS; DEVICE; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; LIFESTYLE; MALE; MEDICAL SPECIALIST; NOSE CONGESTION; PENIS ERECTION; PENIS PROSTHESIS; PHYSICIAN; PRIMARY MEDICAL CARE; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; SEXUAL FUNCTION; SEXUAL INTERCOURSE; SOCIAL ASPECT; VACUUM; VASCULAR SURGERY; VISUAL DISORDER; WELLBEING;

EID: 0036347967     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200210070-00004     Document Type: Review

References (171)

1. NIH consensus development panel on impotence
2. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study
3. Erectile and ejaculatory dysfunction in a community-based sample of men 50 to 78 years old: Prevalence, concern, and relation to sexual activity
4. Practice patterns in the diagnosis and treatment of erectile dysfunction among family practice physicians
5. Trends in the rate of self-report and diagnosis of erectile dysfunction in the United States 1990-1998: Was the introduction of sildenafil an influencing factor?
6. Sildenafil: A review of its use in erectile dysfunction
7. A risk-benefit assessment of sildenafil in the treatment of erectile dysfunction
8. Changing practice patterns in erectile dysfunction: A diagnostic algorithm for the new millennium
9. Recommendations of the 1st international consultation on erectile dysfunction
10. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences
11. Sexual function of men ages 40 to 70 years: The Olmstead County Study of Urinary Symptoms and Health Status Among Men
12. Sexual dysfunction in the United States: Prevalence and predictors
13. Prevalence and independent risk factors for erectile dysfunction in Spain: Results of the Epidemiologia de la Disfuncion Erectil Masculina Study
14. Frequency and determinants of erectile dysfunction in Italy
15. Decline of sexual function with age in Japanese men compared with American men - Results of two community-based studies
16. Sexual desire, erection, orgasm and ejaculatory functions and their importance to elderly Swedish men: A population-based study
17. Epidemiology of erectile dysfunction: Results of the 'Cologne Male Survey'
18. Age-related prevalence of erectile dysfunction in Japan: Assessment by the International Index of Erectile Function
19. Sexual function in 1,202 aging males: Differentiating aspects
20. The process of care model for evaluation and treatment of erectile dysfunction
21. Treatment of erectile dysfunction in men with diabetes
22. The epidemiology and pathophysiology of erectile dysfunction
23. AACE clinical practice guidelines for the evaluation and treatment of male sexual dysfunction
24. Efficacy of sildenafil citrate for the treatment of erectile dysfunction in men taking serotonin reuptake inhibitors
25. An open trial of oral sildenafil in antidepressant-induced sexual dysfunction
26. Erectile dysfunction among healthy men: A population-based study
27. Large prospective study of risk factors for change in erectile function among men over age 50
28. Quality of life assessment in sexual dysfunction trials
29. On life satisfaction in male erectile dysfunction
30. The effect of age, ethnicity and geographical location on impotence and quality of life
31. Intimacy and quality of life among sexually dysfunctional men and women
32. Health-related quality of life in men with erectile dysfunction
33. Erectile dysfunction in patients with diabetes
34. Socioeconomic considerations in erectile dysfunction treatment
35. Economic cost of male erectile dysfunction using a decision analytic model: For a hypothetical managed-care plan of 100,000 members
36. The Dutch cohort of sildenafil users: Baseline characteristics
37. Management of sexual dysfunction in patients with cardiovascular disease: Recommendations of The Princeton Consensus Panel
38. A systematic approach to erectile dysfunction in the cardiovascular patient: A consensus statement
39. UK management guidelines for erectile dysfunction
40. Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors
41. Laparoscopically assisted penile revascularization for vasculogenic impotence
42. Long-term results of arterial bypass surgery for impotence secondary to segmentai vascular disease
43. Penile prosthesis surgery: Review of ten-year experience and examination of reoperations
44. The use of penile protheses in the treatment of impotence
45. Eleven years of experience with the inflatable penile prosthesis
46. External vacuum therapy for erectile dysfunction: Use and results
47. Patient acceptance of and satisfaction with an external negative pressure device for impotence
48. Vacuum constriction and external erection devices in erectile dysfunction
49. Popularity of the vacuum erection device in male sexual dysfunction
50. Reasons of dropout from short- and long-term self-injection therapy for impotence
51. Muse (alprostadil) urethral suppository
52. Comparative tolerability and efficacy of treatments for impotence
53. Pharmacotherapeutic advances in the treatment of erectile dysfunction
54. Is high-dose yohimbine hydrochloride effective in the treatment of mixed-type impotence? A prospective, randomized, controlled double-blind crossover study
55. Yohimbine for erectile dysfunction: A systematic review and meta-analysis of randomised clinical trials
56. Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial
57. Double-blind trial of yohimbine in treatment of psychogenic impotence
58. Trazodone, a double blind trial for treatment of erectile dysfunction
59. Oral trazodone as empirical therapy for erectile dysfunction: A retrospective review
60. Effect of yohimbine-trazodone on psychogenic impotence: A randomised, double-blind, placebo-controlled study
61. Pharmacotherapy of erectile dysfunction: A review
62. Pharmacodynamic interactions between tadalafil and nitrates compared with sildenafil
63. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: The first at-home clinical trial
64. Vardenafil improved erectile function in men with a broad range of erectile dysfunction etiologies and severities: A phase III trial
65. Vardenafil
66. Vardenafil improved erectile function in diabetic men with erectile dysfunction
67. Efficacy and tolerability of vardenafil in men with erectile dysfunction following radical prostatectomy
68. Tadalafil significantly improves erectile function in men with ED: Integrated analysis of registration trials
69. Tadalafil (IC351) taken as needed by diabetic men with erectile dysfunction
70. US delay for Lilly Icos's Cialis
71. Cialis (IC351) provides prompt response and extended period of responsiveness for the treatment of men with erectile dysfunction
72. Tadalafil allows men with erectile dysfunction to have successful intercourse up to 36 hours postdose
73. Intracavernous alprostadil: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction
74. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction
75. Treatment of men with erectile dysfunction with transurethral alprostadil
76. Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting
77. A double-blind, placebo-controlled evaluation of the erectile response to transurethral alprostadil
78. The role of apomorphine SL in the treatment of male erectile dysfunction
79. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction
80. Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction
81. Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates
82. Treatment of impotence by intrapenile injections. A comparison of papaverine versus papaverine and phentolamine: A double-blind, crossover trial
83. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction
84. Intracavernous injection therapy: Analysis of results and complications
85. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes
86. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carnae and aortic rings in vitro
87. Systematic review of randomised controlled trials of sildenafil (Viagra) in the treatment of male erectile dysfunction
88. Oral sildenafil in the treatment of erectile dysfunction
89. Efficacy and safety of oral sildenafil in the treatment of erectile dysfunction: A double-blind, placebo-controlled study of 329 patients
90. Sildenafil, a novel effective oral therapy for male erectile dysfunction
91. Onset and duration of action of sildenafil citrate for the treatment of erectile dysfunction
92. The International Index of Erectile Function (IIEF): A muttidimensional scale for assessment of erectile dysfunction
93. ASSESS-3: A randomised, double-blind, fiexible-dose clinical trial of the efficacy and safety of oral sildenafil in the treatment of men with erectile dysfunction in Taiwan
94. Asian sildenafil efficacy and safety study (ASSESS-1): A double-blind, placebo-controlled, fiexible-dose study of oral sildenafil in Malaysian, Singaporean, and Filipino men with erectile dysfunction
95. Sildenafil (Viagra) in the treatment of male erectile dysfunction in Nairobi
96. Sildenafil citrate (Viagra) in erectile dysfunction: Near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjects
97. Sildenafil citrate for the treatment of erectile dysfunction in men with type II diabetes mellitus
98. Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the Erectile Dysfunction Inventory of Treatment Satisfaction Questionnaire
99. Sildenafil citrate (VIAGRA) improves erectile function in elderly patients with erectile dysfunction: A subgroup analysis
100. Treatment of erectile dysfunction in men with depressive symptoms: Results of a placebo-controlled trial with sildenafil citrate
101. Treatment with sildenafil citrate in renal transplant patients with erectile dysfunction
102. Incidence of erectile dysfunction and efficacy of sildenafil in the cardiac transplantation patient
103. Clinical efficacy of sildenafil in patients on chronic dialysis
104. Erectile dysfunction and the effects of sildenafil treatment in patients on haemodialysis and continuous ambulatory peritoneal dialysis
105. Successful salvage of sildenafil (Viagra) failures and benefits of patient education and re-challenge with sildenafil
106. Assessment of the efficacy and safety of Viagra (sildenafil citrate) in men with erectile dysfunction during long-term treatment
107. Long-term efficacy of Viagra (sildenafil citrate): Results after 2-3 years of treatment
108. Sildenafil: Efficacy and safety in daily clinical experience
109. Efficacy, safety, and use of sildenafil in urologic practice
110. Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction
111. Sildenafil for treatment of erectile dysfunction in men with diabetes: A randomized controlled trial
112. Sildenafil citrate for treatment of erectile dysfunction is similarly effective in men with type 1 and type 2 diabetes mellitus
113. Prevalence of self-reported erectile dysfunction in people with long-term IDDM
114. Efficacy and safety of oral sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury
115. Sildenafil in the treatment of sexual dysfunction in spinal cord-injured male patients
116. A two-part pilot study of sildenafil (VIAGRA) in men with erectile dysfunction caused by spinal cord injury
117. Randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury
118. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension
119. Viagra (sildenafil citrate) for the treatment of erectile dysfunction in men with multiple sclerosis
120. Efficacy and safety of sildenafil citrate for the treatment of erectile dysfunction in men with cardiovascular disease
121. Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease
122. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy
123. Efficacy of Viagra (sildenafil citrate) in men with erectile dysfunction and arterial hypertension who are taking multiple antihypertensive treatments
124. Effect of sildenafil citrate on post-radical prostatectomy erectile dysfunction
125. Prospective pilot study of sildenafil for treatment of postradiotherapy erectile dysfunction in patients with prostate cancer
126. Role of Viagra after radical prostatectomy
127. Sildenafil in the treatment of erectile dysfunction after radical prostatectomy
128. Counselling the patient with prostate cancer about treatment-related erectile dysfunction
129. Sildenafil citrate effectively reverses sexual dysfunction induced by three-dimensional conformal radiation therapy
130. Efficacy of sildenafil citrate in prostate brachytherapy patients with erectile dysfunction
131. Treatment of erectile dysfunction with sildenafil citrate (Viagra) after radiation therapy for prostate cancer
132. Efficacy of oral sildenafil in patients with erectile dysfunction after radiotherapy for carcinoma of the prostate
133. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction
134. Safety of Viagra (sildenafil citrate) in men with erectile dysfunction and arterial hypertension who are taking multiple antihypertensive treatments
135. Ocular safety of Viagra, (sildenafil citrate)
136. Acure type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure
137. Cardiovascular effects of sildenafil citrate (Viagra): A naturalistic cross-over study
138. Incidence of myocardial infarction and death in 53 clinical trials of Viagra (sildenafil citrate)
139. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: A randomized crossover trial
140. Time to onset of limiting angina during treadmill exercise in men with erectile dysfunction and stable chronic angina: Effect of sildenafil citrate
141. Hemodynamic effects of sildenafil in men with severe coronary artery disease
142. Is Sildenafil (Viagra) safe and effective for the treatment of erectile dysfunction in patients with heart failure?
143. Cardiovascular events in users of sildenafil: Results from first phase of prescription event monitoring in England
144. Comparison of reported and expected deaths in sildenafil (Viagra) users
145. Access to innovative treatment of erectile dysfunction: Clinical, economic, and quality-of-life considerations
146. Efficacy results and quality-of-life measures in men receiving sildenafil citrate for the treatment of erectile dysfunction
147. Improvement in emotional well-being and relationships of users of sildenafil
148. Quality of life in patients with spinal cord injury receiving Viagra (sildenafil citrate) for the treatment of erectile dysfunction
149. Lower self-reported depression in patients with erectile dysfunction after treatment with sildenafil
150. Quality of partnership in patients with erectile dysfunction after sildenafil treatment
151. The cost-effectiveness of sildenafil
152. Cost utility analysis of sildenafil compared with papaverine-phentolamine injections
153. Drug coverage decisions: The role of dollars and values
154. Provision of care for patients with erectile dysfunction in managed-Medicare
155. Economic impact of sildenafil citrate treatment among newly diagnosed erectile dysfunction patients in managed care organizations
156. Coverage of sildenafil citrate by employers and health plans: Lower than expected pharmacy benefit costs and additional health benefits
157. Incidence of medically detected erectile dysfunction and related diseases before and after Viagra (sildenafil citrate)
158. Market share shift analysis identifies scenario allowing maximum number of ED patients to be treated
159. Economic analysis of sildenafil citrate add-on to treat SSRI-induced erectile dysfunction
160. Valuing the effects of sildenafil in erectile dysfunction: Strong assumptions are required to generate a QALY value
161. Sildenafil versus intracavernous injection therapy: Efficacy and preference in patients on intracavernous injection for more than 1 year
162. The diffusion of a novel therapy into clinical practice: The case of sildenafil
163. Current treatments and emerging therapeutic approaches in male erectile dysfunction
164. Switching from intracavernous prostaglandin E1 injections to oral sildenafil citrate in patients with erectile dysfunction: Results of a multicenter European study